Merz Pharma Canada in the News
MERZ Pharma Canada Inc. is pleased to announce that effective May 19th 2011, XEOMIN(R) (clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins) has been listed with Limited Use Status on the Ontario Drug Benefit formulary (ODB).
MERZ Pharma Canada Ltd. Is Proud to Announce That XEOMIN(R) Has Listed With Regular Benefit Status on the Alberta Health and Wellness Drug Benefit List (AHWDBL)
Merz Pharmaceuticals Announces Long-Term Efficacy and Safety Data with Repeated Xeomin(R) Injections in Upper Limb Post-Stroke Spasticity
TORONTO, ONTARIO--(Marketwire - June 23, 2010) - British Columbia's Ministry of Health Services announced today that they are accepting the Drug Benefit Council's recommendation and listing Xeomin® on the Pharmacare program formulary as Limited Coverage for the following indications.